TENX

Tenax Therapeutics, Inc.

0.29 USD

Last updated Dec 10, 19:47 UTC

Yesterday HIGH

$0.29

Yesterday LOW

$0.26

52w HIGH

$4.3

52w LOW

$0.15

EPS

-0.08

PE

-3.64

Next Earnings

Apr 1, 2024

Overview News Government Trades

Tenax Therapeutics, Inc. stock is up 81.87% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 December’s closed higher than November. 100% of analysts rate it a buy.

Tenax Therapeutics, Inc. engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company was founded in 1967 and is headquartered in Morrisville, North Carolina.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Morrisville, United States Of America

Website

tenaxthera.com

Benzinga Insights

Fri Sep 29, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights

Thu Sep 28, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Lisa Levin

Mon Sep 18, 2023

Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Gainers
Benzinga Insights

Mon Aug 21, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Lisa Levin

Thu Aug 17, 2023

Why Modular Medical Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket

Gainers Modular Medical, Inc. (NASDAQ: MODD) shares surged 34.3% to $1.37 in pre-market trading after the company announced a partnership with Phillips-Medisize to expand insulin delivery alternatives.
Benzinga Newsdesk

Wed Jul 19, 2023

Tenax Therapeutics Issued U.S. Patent For Oral Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

New U.S. patent provides intellectual property (IP) protection until December 2040, and may qualify for term extension beyond 2040There are currently no FDA-approved treatments for PH-HFpEF, a condition affecting more
Lisa Levin

Mon Jun 12, 2023

Why Oncorus Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket

Gainers Auddia Inc. (NASDAQ: AUUD) shares rose 103.2% to $0.8809 in pre-market trading after gaining around 9% on Friday.
Lisa Levin

Wed May 31, 2023

Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of AR-301 and the clinical study design.
Benzinga Insights

Wed May 31, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Newsdesk

Wed May 31, 2023

Tenax Therapeutics Achieves Major Milestone As USPTO Grants Notice Of Allowance For U.S. Patent Application Covering Use Of Oral Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction

Once granted, this patent will provide intellectual property protection until December 2040, and may qualify for additional U.S. patent term extension beyond 2040 There are currently no FDA approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030